| Field | Specification |
|---|---|
| Mfr No | |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, which is a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B-precursor ALL (Acute lymphoblastic leukemia). In addition, CD19 was the target of the first approved CAR-T cell therapy.
Product Description
CAR-TThe anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, BPS Bioscience, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.
Product Specifications
| Transfection Method | Lentivirus |
|---|---|
| Supplied As | Each vial contains 2 x 106 cells in 1 ml of CryoStor® CS10) |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cells have been screened to confirm the absence of Mycoplasma species.
Safety & Handling
⚠ Avoid freeze/thaw cycles. Donors have been screened and determined negative for: - Hepatitis B (anti-HBc EIA, HBsAg EIA) - Hepatitis C (anti-HCV EIA) - Human Immunodeficiency Virus (HIV-1/HIV-2 plus O) - Human T-Lymphotropic Virus (HTLV-I/II) - HIV-1/HCV/HBV - West Nile Virus - Trypanasoma cruzi Note: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #90184-A, 60690, 79714, 78170
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. The cells have been screened to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
A standard research-use license applies (No). Commercial applications or transfer to other facilities may require a separate license. Contact BPS Bioscience for details.
This stable cell line was generated using Lentivirus for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.